H. Wehring

发表

Cigarette smoking and mortality risk in people with schizophrenia.

D. Kelly, R. McMahon, H. Wehring, 2011, Schizophrenia bulletin.

Analysis of Pharmacist-Provided Medication Therapy Management(MTM) Services in Community Pharmacies Over 7 Years

H. Wehring, M. Barnett, P. Perry, 2009, Journal of managed care pharmacy : JMCP.

Comparison of Risk of Cerebrovascular Events in an Elderly VA Population With Dementia Between Antipsychotic and Nonantipsychotic Users

H. Wehring, M. Barnett, P. Perry, 2007, Journal of clinical psychopharmacology.

Risk-taking in schizophrenia and controls with and without cannabis dependence

D. Kelly, R. McMahon, H. Wehring, 2015, Schizophrenia Research.

The Family Value of Information, Community Support, and Experience Study: Rationale, Design, and Methods of a “Family-Centered” Research Study

J. Schiffman, H. Wehring, R. Love, 2015, The Journal of nervous and mental disease.

Blood Draw Barriers for Treatment with Clozapine and Development of a Point-of-Care Monitoring Device.

Eunkyoung Kim, G. Payne, D. Kelly, 2015, Clinical schizophrenia & related psychoses.

Current status of clozapine in the United States

D. Kelly, H. Wehring, Gopal R. Vyas, 2012, Shanghai archives of psychiatry.

Telepsychotherapy with Youth at Clinical High Risk for Psychosis: Clinical Issues and Best Practices during the COVID-19 Pandemic.

Shauna P. Reinblatt, J. Schiffman, H. Wehring, 2020, Journal of psychotherapy integration.

Relationship of Interferon-γ to Cognitive Function in Midlife Women with Schizophrenia

D. Kelly, H. Wehring, L. Rubin, 2018, Psychiatric Quarterly.

Diabetes Mellitus Associated with Clozapine Therapy

H. Wehring, P. Perry, B. Alexander, 2000, Pharmacotherapy.

Cardiovascular Disease Mortality in Chronic Schizophrenia Patients Treated with Clozapine

R. Conley, D. Kelly, H. Wehring, 2013 .

Pediatrics Efficacy and Safety of Naltrexone Use in Pediatric Patients with Autistic Disorder

H. Wehring, Nicole M. Maisch, Gladys M Eichaar, 2006, The Annals of pharmacotherapy.

25-Hydroxyvitamin D and metabolic-related laboratory values in women with schizophrenia and hyperprolactinemia.

Megan M. Powell, D. Kelly, H. Wehring, 2022, Journal of psychiatric research.

Pharmacokinetics and Safety Assessment of l‐Tetrahydropalmatine in Cocaine Users: A Randomized, Double‐Blind, Placebo‐Controlled Study

D. Kelly, H. Wehring, S. Feldman, 2017, Journal of clinical pharmacology.

Treatments for the Prevention and Management of Suicide

D. Kelly, H. Wehring, R. Buchanan, 2020, Annals of Internal Medicine.

Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder

D. Kelly, H. Wehring, Kimberly R. Warren, 2013, Schizophrenia Research.

Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels

D. Kelly, H. Wehring, S. Feldman, 2018, Psychiatric Quarterly.

34 Psychopharmacology and Other Somatic Therapies

H. Wehring, P. Perry, B. Liskow, 2008 .

Clinical Psychopharmacology and Other Somatic Therapies

H. Wehring, P. Perry, B. Liskow, 2008 .

Progress examination for assessing students' readiness for advanced pharmacy practice experiences.

H. Wehring, K. Knapp, M. Barnett, 2009, American journal of pharmaceutical education.

L-Tetrahydropalmatine, a Novel Dopamine Antagonist, Fails to Improve Psychiatric Symptoms as Adjunctive Treatment for Schizophrenia

D. Kelly, H. Wehring, S. Hoag, 2020, Schizophrenia Bulletin Open.

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

F. Dickerson, D. Kelly, H. Wehring, 2013, BMC Psychiatry.

Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study

Megan M. Powell, D. Kelly, H. Wehring, 2019, Journal of psychiatry & neuroscience : JPN.

Violence and schizophrenia.

H. Wehring, W. Carpenter, 2011, Schizophrenia bulletin.

Clinical characteristics of heavy and non-heavy smokers with schizophrenia

D. Kelly, H. Wehring, Kristen M. Mackowick, 2012, Schizophrenia Research.

Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia.

D. Kelly, H. Wehring, S. Feldman, 2012, Schizophrenia bulletin.

Undiagnosed Lyme disease in adults with schizophrenia

D. Kelly, H. Wehring, S. Feldman, 2015, Schizophrenia Research.

Tobacco craving in smokers with and without schizophrenia

D. Kelly, H. Wehring, S. Feldman, 2011, Schizophrenia Research.

Anti-aggressive effects of clozapine in involuntarily committed black patients with severe mental illness

D. Kelly, H. Wehring, R. Love, 2022, Schizophrenia Research.

Illicit drug use in heavy smokers with and without schizophrenia

D. Kelly, H. Wehring, Kristen M. Mackowick, 2012, Schizophrenia Research.

Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial

Megan M. Powell, F. Dickerson, D. Kelly, 2018, Journal of clinical psychopharmacology.

Urine testing for antipsychotics: a pilot trial for a method to determine detection levels

D. Kelly, H. Wehring, S. Feldman, 2015, Human psychopharmacology.

Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia

D. Kelly, H. Wehring, S. Feldman, 2017, Journal of dual diagnosis.

Effective Medications for Treating Psychosis in School-Aged Youth

J. Schiffman, H. Wehring, Zachary B. Millman, 2019, School Psychopharmacology.

Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms

D. Kelly, H. Wehring, R. Buchanan, 2011, Schizophrenia Research.

CYP2D6 polymorphisms and atypical antipsychotic weight gain

H. Wehring, Del D. Miller, Stephan Arndt, 2002, Psychiatric genetics.

The Effects of a Gluten-Free Diet on Immune Markers and Kynurenic Acid Pathway Metabolites in Patients With Schizophrenia Positive for Antigliadin Antibodies Immunoglobulin G.

Megan M. Powell, D. Kelly, H. Wehring, 2020, Journal of clinical psychopharmacology.

Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms

D. Kelly, H. Wehring, S. Feldman, 2015, Journal of clinical psychopharmacology.

A review of anti-inflammatory agents for symptoms of schizophrenia

D. Kelly, H. Wehring, R. Buchanan, 2013, Journal of psychopharmacology.

Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia: A Randomized, Double-Blind, Pilot Study

R. Conley, D. Kelly, H. Wehring, 2011, Journal of clinical psychopharmacology.

Effects of Cigarette Smoking and Clozapine Treatment on 20-Year All-Cause & Cardiovascular Mortality in Schizophrenia

D. Kelly, H. Wehring, R. Love, 2019, Psychiatric Quarterly.

Peripheral oxytocin and vasopressin are associated with clinical symptom severity and cognitive functioning in midlife women with chronic schizophrenia

C. Carter, D. Kelly, H. Wehring, 2017, Schizophrenia Research.

Pharmacotherapy of Disruptive and Impulse Control Disorders

H. Wehring, M. Riddle, G. Reeves, 2017 .

Predictors of the Perception of Smoking Health Risks in Smokers With or Without Schizophrenia

William J. Kowalczyk, D. Kelly, H. Wehring, 2017, Journal of dual diagnosis.

Oxytocin and sexual function in males and females with schizophrenia

D. Kelly, H. Wehring, S. Feldman, 2018, Schizophrenia Research.

Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics.

H. Wehring, M. Barnett, P. Perry, 2010, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

D. Kelly, H. Wehring, S. Feldman, 2009, Schizophrenia Research.

Peripheral Cortisol and Inflammatory Response to a Psychosocial Stressor in People with Schizophrenia

D. Kelly, H. Wehring, L. Rowland, 2018, Journal of neuropsychiatry.

The Effect of Intranasal Oxytocin on Measures of Social Cognition in Schizophrenia: A Negative Report

D. Kelly, H. Wehring, R. Buchanan, 2019, Journal of psychiatry and brain science.

Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: Results from a randomized double blind placebo controlled pilot study

D. Kelly, H. Wehring, R. Buchanan, 2013, Schizophrenia Research.

The Potential Role of Long-Acting Injectable Antipsychotics in People With Schizophrenia and Comorbid Substance Use

D. Kelly, H. Wehring, M. Koola, 2012, Journal of dual diagnosis.

INSTRUCTIONAL DESIGN AND ASSESSMENT Progress Examination for Assessing Students' Readiness for Advanced Pharmacy Practice Experiences

H. Wehring, K. Knapp, M. Barnett, 2009 .

Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia

D. Kelly, H. Wehring, R. Buchanan, 2016, Schizophrenia Research.

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection

D. Kelly, H. Wehring, M. Koola, 2011, Journal of central nervous system disease.

Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders.

D. Kelly, H. Wehring, Kristen M. Mackowick, 2012, Journal of psychiatric research.

Effects of intranasal oxytocin on satiety signaling in people with schizophrenia

D. Kelly, H. Wehring, Kimberly R. Warren, 2018, Physiology & Behavior.

Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.

R. Conley, D. Kelly, H. Wehring, 2010, The Journal of clinical psychiatry.

Anti-inflammatory Combination Therapy for the Treatment of Schizophrenia.

D. Kelly, H. Wehring, J. Gold, 2020, Journal of clinical psychopharmacology.

College of Psychiatric and Neurologic Pharmacists 2012 Poster Abstracts

Hepburn, D. Kelly, H. Wehring, 2012 .

ADJUNCTIVE MINOCYCLINE IN CLOZAPINE TREATED SCHIZOPHRENIA PATIENTS

D. Kelly, H. Wehring, S. Feldman, 2014, Schizophrenia Research.

Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial

D. Kelly, H. Wehring, R. Love, 2023, Schizophrenia Research.

Illicit drug use in heavy smokers with and without schizophrenia

D. Kelly, H. Wehring, Kristen M. Mackowick, 2012, Schizophrenia Research.